MX2022006045A - Metodos de administracion de voxelotor. - Google Patents
Metodos de administracion de voxelotor.Info
- Publication number
- MX2022006045A MX2022006045A MX2022006045A MX2022006045A MX2022006045A MX 2022006045 A MX2022006045 A MX 2022006045A MX 2022006045 A MX2022006045 A MX 2022006045A MX 2022006045 A MX2022006045 A MX 2022006045A MX 2022006045 A MX2022006045 A MX 2022006045A
- Authority
- MX
- Mexico
- Prior art keywords
- voxelotor
- methods
- administering
- avoiding
- inhibitor
- Prior art date
Links
- FWCVZAQENIZVMY-UHFFFAOYSA-N 2-hydroxy-6-[[2-(2-propan-2-ylpyrazol-3-yl)pyridin-3-yl]methoxy]benzaldehyde Chemical compound CC(C)N1N=CC=C1C1=NC=CC=C1COC1=CC=CC(O)=C1C=O FWCVZAQENIZVMY-UHFFFAOYSA-N 0.000 title abstract 4
- 229940070141 voxelotor Drugs 0.000 title abstract 4
- 208000009011 Cytochrome P-450 CYP3A Inhibitors Diseases 0.000 abstract 2
- 208000000130 Cytochrome P-450 CYP3A Inducers Diseases 0.000 abstract 1
- 206010013710 Drug interaction Diseases 0.000 abstract 1
- 230000002411 adverse Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000003993 interaction Effects 0.000 abstract 1
- 208000019423 liver disease Diseases 0.000 abstract 1
- 208000007056 sickle cell anemia Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se proporcionan en la presente métodos de uso de voxelotor para el tratamiento de la enfermedad de células falciformes en pacientes que también tienen insuficiencia hepática grave. También se proporcionan en la presente métodos para administrar voxelotor y evitar o disminuir las interacciones farmacológicas adversas con un inductor o inhibidor de CYP3A4. También se proporcionan en la presente métodos para evitar interacciones con voxelotor, un inhibidor moderado de CYP3A4.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962937706P | 2019-11-19 | 2019-11-19 | |
| US201962940154P | 2019-11-25 | 2019-11-25 | |
| PCT/US2020/060923 WO2021101910A1 (en) | 2019-11-19 | 2020-11-17 | Methods of administering voxelotor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022006045A true MX2022006045A (es) | 2022-08-15 |
Family
ID=73835728
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022006045A MX2022006045A (es) | 2019-11-19 | 2020-11-17 | Metodos de administracion de voxelotor. |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230015823A1 (es) |
| EP (1) | EP4061368A1 (es) |
| BR (1) | BR112022009522A2 (es) |
| CA (1) | CA3161761A1 (es) |
| IL (1) | IL292982A (es) |
| MX (1) | MX2022006045A (es) |
| WO (1) | WO2021101910A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL312447A (en) * | 2021-11-05 | 2024-06-01 | Global Blood Therapeutics Inc | Methods of treating sickle cell disease with Oxbryta |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20181519A1 (es) | 2011-12-28 | 2018-09-21 | Global Blood Therapeutics Inc | Compuestos de benzaldehido sustituidos y metodos para su uso en incrementar la oxigenacion del tejido |
| JP6809681B2 (ja) | 2014-02-07 | 2021-01-06 | グローバル ブラッド セラピューティクス インコーポレイテッド | ２−ヒドロキシ−６−（（２−（１−イソプロピル−１ｈ−ピラゾール−５−イル）ピリジン−３−イル）メトキシ）ベンズアルデヒドの遊離塩基の結晶多形 |
| US11020382B2 (en) | 2015-12-04 | 2021-06-01 | Global Blood Therapeutics, Inc. | Dosing regimens for 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde |
| TWI663160B (zh) | 2016-05-12 | 2019-06-21 | 全球血液治療公司 | 用於合成2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)-吡啶-3-基)甲氧基)苯甲醛之方法 |
| TW202332423A (zh) | 2016-10-12 | 2023-08-16 | 美商全球血液治療公司 | 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑 |
-
2020
- 2020-11-17 US US17/777,909 patent/US20230015823A1/en active Pending
- 2020-11-17 WO PCT/US2020/060923 patent/WO2021101910A1/en not_active Ceased
- 2020-11-17 IL IL292982A patent/IL292982A/en unknown
- 2020-11-17 BR BR112022009522A patent/BR112022009522A2/pt unknown
- 2020-11-17 CA CA3161761A patent/CA3161761A1/en active Pending
- 2020-11-17 EP EP20824753.6A patent/EP4061368A1/en active Pending
- 2020-11-17 MX MX2022006045A patent/MX2022006045A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4061368A1 (en) | 2022-09-28 |
| US20230015823A1 (en) | 2023-01-19 |
| CA3161761A1 (en) | 2021-05-27 |
| WO2021101910A1 (en) | 2021-05-27 |
| IL292982A (en) | 2022-07-01 |
| BR112022009522A2 (pt) | 2022-08-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12020551578A1 (en) | Modulators of methyl modifying enzymes, compositions and uses thereof | |
| MX2020007625A (es) | Inhibidor mtor, composicion farmaceutica y su uso. | |
| MX2023003677A (es) | Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos. | |
| MX2023003678A (es) | Inhibidores de hidroxiesteroide 17beta- deshidrogenasa 13 (hsd17b13) y usos de estos. | |
| EP4497474A3 (en) | Methods of treating rheumatic diseases using trimetazidine-based compounds | |
| CL2019003496A1 (es) | Métodos de tratamiento de pacientes con enfermedad de fabry que tienen insuficiencia renal. | |
| PH12019500208A1 (en) | Spiro-lactam nmda receptor modulators and methods of using same | |
| PH12021550605A1 (en) | Farnesoid x receptor agonists and uses thereof | |
| PH12019500202A1 (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| MX2024008461A (es) | Metodos para tratar trastornos linfoproliferativos malignos. | |
| MX2016011333A (es) | Sistemas de administracion de farmaco y metodo para el tratamiento de cancer de vejiga con gemcitabina. | |
| AU2018326364A1 (en) | Methods of enhancing and/or stabilizing cardiac function in patients with Fabry disease | |
| EP3590338A3 (en) | Medical treatments based on anamorelin | |
| MX390722B (es) | Tratamiento de resistencia a diureticos. | |
| WO2019175260A3 (en) | Modified oligonucleotides for use in treatment of tauopathies | |
| MX2023003675A (es) | Inhibidores de hidroxiesteroide 17beta-deshidrogenasa 13 (hsd17b13) y usos de estos. | |
| MX2021003606A (es) | Compuestos de bifenil-sulfonamida para el tratamiento de enfermedades de colageno tipo iv. | |
| WO2022178255A3 (en) | Single domain antibodies that neutralize sars-cov-2 | |
| MX2021009051A (es) | Tratamiento de lesiones cutaneas y prurito en pacientes con prurigo nodular. | |
| EP4470615A3 (en) | Small rna medicament for prevention and treatment of inflammation-related diseases and combination thereof | |
| MX2022006045A (es) | Metodos de administracion de voxelotor. | |
| PH12021550121A1 (en) | Methods of treating hfpef employing dapagliflozin and compositions comprising the same | |
| MX2021013351A (es) | Terapias de combinacion. | |
| MX2018010096A (es) | Tratamiento de pacientes con hipercolesterolemia familiar homocigota en terapia de disminucion de lipidos. | |
| MX2020000118A (es) | Composiciones y metodos para mejorar la funcion cardiaca. |